Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
July 15, 2025
Innovative Technology Insights
Navigating FDA’s Proposed Guidance on AI and Non-Animal Models: Safeguarding Innovation in Drug Development
In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in…
July 15, 2025
Health Care Law Today
Navigating FDA’s Proposed Guidance on AI and Non-Animal Models: Safeguarding Innovation in Drug Development
In April 2025, the U.S. Food and Drug Administration (FDA) released a landmark guidance titled “Roadmap to Reducing Animal Testing in…
July 15, 2025
Health Care Law Today
Colorado Medicaid: RAC Program Overhauled with Enhanced Transparency, Greater Provider Protections, and Increased Oversight
In June 2025, Colorado passed a new law that makes significant changes to the state’s Medicaid Recovery Audit Contractor (RAC) program….